• Something wrong with this record ?

Prognostic Significance of Inflammation-based Scores in Pancreatic Cancer Patients Treated With Palliative Chemotherapy: A Single Institution Experience

M. Liberko, T. Sychra, M. Oliverius, R. Soumarová

. 2024 ; 38 (6) : 2782-2794. [pub] -

Language English Country Greece

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25003579

BACKGROUND/AIM: Inflammation-based prognostic scores have shown prognostic significance and have been associated with clinical outcomes in various types of cancer. Inflammation is known to promote tumor progression leading to reduced survival. In pancreatic cancer, systemic inflammation is common and contributes to its dismal prognosis. Although the prognosis of pancreatic cancer is improving with the introduction of new drugs, the prognostic indicators are still poorly understood. The present study aimed to evaluate inflammation-based prognostic scores in patients with metastatic pancreatic cancer receiving first-line chemotherapy. PATIENTS AND METHODS: A total of 43 patients with metastatic pancreatic cancer undergoing first-line chemotherapy (gemcitabine+nab-paclitaxel and mFOLFIRINOX) in our institution were analyzed. Baseline clinicopathological and pre-treatment laboratory data were collected. Survival was estimated using the Kaplan-Meier method and survival differences were evaluated using the log-rank test. RESULTS: In the whole cohort, we identified lymphocyte-to-monocyte ratio ≥3, systemic inflammatory response index <2.3, carcinoembryonic antigen <2.5, neutrophil-to-lymphocyte ratio <5, Memorial Sloane Kettering score <2, and prognostic index <2 as prognostic markers associated with improved overall survival in patients receiving first-line chemotherapy. CONCLUSION: The current analysis showed an association between inflammatory-based prognostic markers and overall survival in patients with metastatic pancreatic cancer treated in a real-world setting at a single institution.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003579
003      
CZ-PrNML
005      
20250206104427.0
007      
ta
008      
250121s2024 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.13758 $2 doi
035    __
$a (PubMed)39477392
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Liberko, Marián $u Department of Oncology, University Hospital Kralovske Vinohrady, Prague, Czech Republic; marian.liberko@fnkv.cz $u Third Faculty of Medicine, Charles University, Department of Oncology, Prague, Czech Republic
245    10
$a Prognostic Significance of Inflammation-based Scores in Pancreatic Cancer Patients Treated With Palliative Chemotherapy: A Single Institution Experience / $c M. Liberko, T. Sychra, M. Oliverius, R. Soumarová
520    9_
$a BACKGROUND/AIM: Inflammation-based prognostic scores have shown prognostic significance and have been associated with clinical outcomes in various types of cancer. Inflammation is known to promote tumor progression leading to reduced survival. In pancreatic cancer, systemic inflammation is common and contributes to its dismal prognosis. Although the prognosis of pancreatic cancer is improving with the introduction of new drugs, the prognostic indicators are still poorly understood. The present study aimed to evaluate inflammation-based prognostic scores in patients with metastatic pancreatic cancer receiving first-line chemotherapy. PATIENTS AND METHODS: A total of 43 patients with metastatic pancreatic cancer undergoing first-line chemotherapy (gemcitabine+nab-paclitaxel and mFOLFIRINOX) in our institution were analyzed. Baseline clinicopathological and pre-treatment laboratory data were collected. Survival was estimated using the Kaplan-Meier method and survival differences were evaluated using the log-rank test. RESULTS: In the whole cohort, we identified lymphocyte-to-monocyte ratio ≥3, systemic inflammatory response index <2.3, carcinoembryonic antigen <2.5, neutrophil-to-lymphocyte ratio <5, Memorial Sloane Kettering score <2, and prognostic index <2 as prognostic markers associated with improved overall survival in patients receiving first-line chemotherapy. CONCLUSION: The current analysis showed an association between inflammatory-based prognostic markers and overall survival in patients with metastatic pancreatic cancer treated in a real-world setting at a single institution.
650    _2
$a lidé $7 D006801
650    12
$a nádory slinivky břišní $x farmakoterapie $x mortalita $x patologie $7 D010190
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prognóza $7 D011379
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    12
$a paliativní péče $x metody $7 D010166
650    12
$a zánět $x patologie $x farmakoterapie $7 D007249
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a gemcitabin $7 D000093542
650    _2
$a fluoruracil $x aplikace a dávkování $x terapeutické užití $7 D005472
650    _2
$a deoxycytidin $x analogy a deriváty $x aplikace a dávkování $x terapeutické užití $7 D003841
650    _2
$a paclitaxel $x aplikace a dávkování $7 D017239
650    _2
$a irinotekan $x aplikace a dávkování $x terapeutické užití $7 D000077146
650    _2
$a leukovorin $x aplikace a dávkování $x terapeutické užití $7 D002955
650    _2
$a dospělí $7 D000328
650    _2
$a oxaliplatin $x aplikace a dávkování $x terapeutické užití $7 D000077150
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a neutrofily $x patologie $7 D009504
650    _2
$a albuminy $x aplikace a dávkování $7 D000418
650    _2
$a senioři nad 80 let $7 D000369
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sychra, Tomáš $u Third Faculty of Medicine, Charles University, Department of Oncology, Prague, Czech Republic $u Department of General Surgery, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Oliverius, Martin $u Third Faculty of Medicine, Charles University, Department of Oncology, Prague, Czech Republic $u Department of General Surgery, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Soumarová, Renata $u Department of Oncology, University Hospital Kralovske Vinohrady, Prague, Czech Republic $u Third Faculty of Medicine, Charles University, Department of Oncology, Prague, Czech Republic
773    0_
$w MED00175831 $t In Vivo $x 1791-7549 $g Roč. 38, č. 6 (2024), s. 2782-2794
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39477392 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104422 $b ABA008
999    __
$a ok $b bmc $g 2263371 $s 1239586
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 38 $c 6 $d 2782-2794 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options